NEU 1.14% $19.52 neuren pharmaceuticals limited

Its good to have a published report validating things we...

  1. 13,916 Posts.
    lightbulb Created with Sketch. 124
    Its good to have a published report validating things we shareholders already know.

    While I love the 12mth target price, I think we need the benefit of getting past Phase II results. NNZ-2566 may be the ducks nuts in pre-clinical but it really needs validation in humans to get us noticed by the big end of town.

    If we get it, 12c will be too cheap for this stock.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.